Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 3Lung Neoplasms 3Breast Neoplasms 3Respiratory Insufficiency 1Radiation Pneumonitis 1Prostatic Neoplasms 1Parkinson Disease 1Lymphoma, Non-Hodgkin 1Lung Diseases 1Hodgkin Disease 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Abnormalities, Radiation-Induced 1

Interventions

fluorodopa F 18 2Tomography, Emission-Computed, Single-Photon 1Registries 1Positron Emission Tomography Computed Tomography 1Neuropsychological Tests 1Neurofeedback 1Medical Marijuana 1Iodine-124 1Iodine-123 1Furosemide 1Exergaming 1Clinical Laboratory Techniques 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease × Tomography, Emission-Computed, Single-Photon × Clear all
NCT01931488 2013-08-29

124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.

Tel-Aviv Sourasky Medical Center

Phase 2 Unknown
40 enrolled
EndocrineNET

Parkinson Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡